To the full analysis
Buyback calculator for Celldex Therapeutics
Celldex Therapeutics stock: key metrics
CLDXCelldex Therapeutics had an operating margin of −19,160% and a return on invested capital (ROIC) of −35.3% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2006 | 100.0% | −453.6% | −413.2% |
| 2007 | 100.0% | −447.9% | −424.0% |
| 2008 | 100.0% | −456.0% | −637.1% |
| 2009 | 44.7% | −216.4% | −240.6% |
| 2010 | 74.2% | −13.8% | −5.4% |
| 2011 | 1.6% | −468.4% | −483.5% |
| 2012 | 3.8% | −518.5% | −527.8% |
| 2013 | 43.2% | −1,981.1% | −1,983.7% |
| 2014 | 5.2% | −3,414.1% | −3,292.8% |
| 2015 | 26.8% | −2,363.9% | −2,321.1% |
| 2016 | −1,403.5% | −1,958.7% | −1,894.0% |
| 2017 | −654.7% | −953.7% | −730.1% |
| 2018 | −596.7% | −1,640.1% | −1,585.1% |
| 2019 | −1,094.3% | −1,540.2% | −1,424.0% |
| 2020 | −473.4% | −854.1% | −805.9% |
| 2021 | −1,046.2% | −1,531.8% | −1,516.0% |
| 2022 | −3,389.9% | −4,889.0% | −4,765.6% |
| 2023 | −1,614.5% | −2,245.3% | −2,054.8% |
| 2024 | −2,229.8% | −2,778.9% | −2,248.8% |
| 2025 | 100.0% | −19,160.0% | −17,253.3% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2006 | −100.0% | −34.1% | −33.1% |
| 2007 | 113.6% | −45.0% | −57.5% |
| 2008 | −100.0% | −63.7% | −68.1% |
| 2009 | −49.5% | −28.2% | −26.0% |
| 2010 | −3.4% | −24.1% | −2.3% |
| 2011 | −65.2% | −35.3% | −45.7% |
| 2012 | −61.7% | −45.1% | −47.1% |
| 2013 | −25.5% | −29.2% | −23.5% |
| 2014 | −55.8% | −35.0% | −47.6% |
| 2015 | −43.8% | −38.1% | −37.7% |
| 2016 | −48.4% | −31.8% | −33.5% |
| 2017 | −39.4% | −29.9% | −29.5% |
| 2018 | −100.0% | −55.9% | −97.0% |
| 2019 | −54.1% | −33.6% | −41.4% |
| 2020 | −28.6% | −30.1% | −25.3% |
| 2021 | −16.8% | −17.3% | −15.9% |
| 2022 | −34.4% | −23.9% | −31.8% |
| 2023 | −33.0% | −31.8% | −30.4% |
| 2024 | −21.1% | −26.0% | −19.9% |
| 2025 | −49.1% | −35.3% | −44.4% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Oct 2006)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.